NEW YORK (GenomeWeb News) – NeoGenomics Laboratories will offer Signal Genetics' new gene expression profile test for multiple myeloma to pathologists and hospital-based hematologists and oncologists nationwide under a deal announced today.
Under the terms of the agreement, Signal Genetics' Myeloma Prognostic Risk Signature test will be performed at its CLIA-certified laboratory in Little Rock, Ark., and results will be incorporated into NeoGenomics' test reports to be provided to its customers along with other ancillary diagnostic tests, Signal Genetics said.
NeoGenomics also has been granted right of first negotiation to market any genomic and transcriptomic-based diagnostic test developed and/or launched by Signal Genetics in the future to pathologists and hospital-based hematologists and oncologists.
No further terms of the deal were disclosed.
According to Signal Genetics, the MyPRS test provides the most detailed expression profiling information for multiple myeloma patients currently available on the market. Using a proprietary algorithm, it analyzes a defined number of relevant genes to determine the gene expression profile associated with a patient's condition, giving physicians a predictive view of the patient's progress and enabling personalized treatment decisions.
MyPRS is currently available to community-based hematologists and medical oncologists through a deal with Caris Life Sciences. In a statement, Joe Hernandez, CEO of Signal Genetics, said today's agreement "expands our partnerships with key players in the molecular diagnostics marketplace and provides potential vehicles by which to commercialize additional products currently in our pipeline."
Last month, the New York-based firm announced a deal with Pronto Diagnostics to distribute MyPRS in Israel. Signal Genetics is the parent company of Myeloma Health and Respira Health.